389 related articles for article (PubMed ID: 28124939)
21. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Lin TE; Adams KF; Patterson JH
Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
[TBL] [Abstract][Full Text] [Related]
22. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
Urso C; Brucculeri S; Caimi G
J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
[TBL] [Abstract][Full Text] [Related]
23. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
[TBL] [Abstract][Full Text] [Related]
24. Tolvaptan for hyponatremia.
Ozkan C; Kirkpantur A; Arici M
N Engl J Med; 2007 Mar; 356(9):962; author reply 962-3. PubMed ID: 17338053
[No Abstract] [Full Text] [Related]
25. Hyponatremia in cirrhosis: pathophysiology and management.
John S; Thuluvath PJ
World J Gastroenterol; 2015 Mar; 21(11):3197-205. PubMed ID: 25805925
[TBL] [Abstract][Full Text] [Related]
26. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
27. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Gaglio P; Marfo K; Chiodo J
Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
29. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
Rollino C; Balbiano R; Caramello P; Roccatello D
G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and management of hyponatremia in cancer patients.
Castillo JJ; Vincent M; Justice E
Oncologist; 2012; 17(6):756-65. PubMed ID: 22618570
[TBL] [Abstract][Full Text] [Related]
31. Tolvaptan for hyponatremia.
Weise WJ; Rimmer JM; Hood VL
N Engl J Med; 2007 Mar; 356(9):961; author reply 962-3. PubMed ID: 17329708
[No Abstract] [Full Text] [Related]
32. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
[TBL] [Abstract][Full Text] [Related]
33. [Hyponatremia--with comments on hypernatremia].
Palm C; Reimann D; Gross P
Ther Umsch; 2000 Jun; 57(6):400-7. PubMed ID: 10894027
[TBL] [Abstract][Full Text] [Related]
34. [Hyponatremia : The water-intolerant patient].
Hensen J
Med Klin Intensivmed Notfmed; 2012 Sep; 107(6):440-7. PubMed ID: 22911166
[TBL] [Abstract][Full Text] [Related]
35. [Syndrome of inadequate ADH secretion: pitfalls in diagnosis and therapy].
Schäffler A; Lindner U
Dtsch Med Wochenschr; 2015 Mar; 140(5):343-6. PubMed ID: 25734677
[TBL] [Abstract][Full Text] [Related]
36. [Hyponatremia].
Heinrich S; Wagner A; Gross P
Med Klin Intensivmed Notfmed; 2013 Feb; 108(1):53-8. PubMed ID: 22948253
[TBL] [Abstract][Full Text] [Related]
37. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
Gross PA; Wagner A; Decaux G
Kidney Int; 2011 Sep; 80(6):594-600. PubMed ID: 21451459
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness and adequacy of tolvaptan prescription in hospitalized patients].
Edo Solsona MD; Ruiz Ramos J; Montero Hernández M; Font Noguera I; Poveda Andrés JL
Farm Hosp; 2013; 37(3):178-81. PubMed ID: 23789795
[TBL] [Abstract][Full Text] [Related]
39. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
40. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
